310880-25-2

Basic information

• Product Name: Ethanamine, 2-(3-pyridinyloxy)- (9CI)
• Synonyms: Ethanamine, 2-(3-pyridinyloxy)- (9CI);2-(Pyridin-3-yloxy)ethanaMine;3-(2-AMinoethoxy)pyridine;2-(3-Pyridinyloxy)ethylamine;2-(3-Pyridinyloxy)ethanamine;2-(pyridin-3-yloxy)ethanamine HCl
• CAS NO: 310880-25-2
• Molecular Formula: C₇H₁₀N₂O
• Molecular Weight: 138.1671
• Product Categories: PYRIDINE
• Mol File: 310880-25-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 258.8±20.0 °C(Predicted)
• Appearance: /
• Density: 1.089±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.08±0.10(Predicted)
• CAS DataBase Reference: Ethanamine, 2-(3-pyridinyloxy)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanamine, 2-(3-pyridinyloxy)- (9CI)(310880-25-2)
• EPA Substance Registry System: Ethanamine, 2-(3-pyridinyloxy)- (9CI)(310880-25-2)

Safety Data

• Hazardous Substances Data: 310880-25-2(Hazardous Substances Data)

Usage

General Description

Ethanamine, 2-(3-pyridinyloxy)- (9CI) is a chemical compound with the molecular formula C7H10N2O. It is also known as 3-pyridyloxyethylamine and is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceuticals. Ethanamine, 2-(3-pyridinyloxy)- (9CI) is a clear liquid with a slightly sweet odor, and it is flammable in nature. It is important to handle and store this chemical with caution, following all safety procedures and guidelines to prevent any potential hazards. Additionally, it is important to use personal protective equipment when working with this compound to minimize exposure and potential health risks.

Upstream product

• 109-00-2 3-HYDROXYPYRIDINE 
• 266348-17-8 2-(pyridin-3-yloxy)acetonitrile 
• 1336-21-6 ammonium hydroxide 
• 52536-10-4 3-(2-chloroethoxy)pyridine 

Relevant articles and documents

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The invention relates to the field of medicine, discloses new nitrogen heterocyclic derivatives, preparation method thereof and as medicament in particular as the treatment and prevention of treating tissue fibrosis of the medicament. The invention also discloses a pharmaceutically acceptable compound of the present invention comprise a pharmaceutical composition and methods for using the composition for the treatment of the human or animal tissue fibrosis of diseases, in particular for treating the human or animal renal interstitial fibrosis, glomerular sclerosis, hepatic fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, skin fibrosis, after the operation of adhering, benign prostate hypertrophy, bone-myocardial, scleroderma, multiple sclerosis, pancreas fibrosis, liver cirrhosis, myosarcoma, neurofibromatosis, interstitial pulmonary fibrosis, diabetic nephropathy, Alzheimer's disease or vascular fibrosis disease in use. (by machine translation)

Pharmaceutical compositions and methods for use

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines. Exemplary compounds include dimethyl(2-(3-pyridyloxy)ethylamine, dimethyl(4-(3-pyridyloxy)butyl)amine, 2-(3-pyridyloxy)ethylamine, 4-(3-pyridyloxy)butylamine, methyl(3-(5-methoxy-3-pyridyloxy)propyl)amine, ethyl(3-(3-pyridyloxy)propyl)amine, methyl(2-(3-pyridyloxy)ethyl)amine, methyl(3-(6-methyl(3-pyridyloxy))propyl)amine, (3-(3-methoxyphenoxy)propyl)methylamine, (3-(5-chloro(3-pyridyloxy))-1-methylpropyl)methylamine, dimethyl(3-(3-pyridyloxy)propyl)amine, 3-(3-pyridyloxy)propylamine, methyl(4-(3-pyridyloxy)butyl)amine, 3-(5-chloro-3-pyridyloxy)propylamine, methyl(3-(5-isopropoxy-3-pyridyloxy)propyl)amine, (3-(5-chloro(3-pyridyloxy))propyl)methylamine, methyl(3-(5-(phenylmethoxy)(3-pyridyloxy))propyl)amine, methyl(3-(2-methyl(3-pyridyloxy))propyl)amine, (methylethyl)(3-(3-pyridyloxy)propyl)amine, benzyl(3-(3-pyridyloxy)propyl)amine, cyclopropyl(3-(3-pyridyloxy)-propyl)amine, methyl(1-methyl-3-(3-pyridyloxy)propyl)amine, methyl(3-(3-nitrophenoxy)propyl)amine, 1-(3-chloropropoxy)-3-nitrobenzene, (3-(3-aminophenoxy)propyl)methylamine, dimethyl(3-(3-(methylamino)-propoxy)phenyl)amine, methyl(3-tricyclo[7.3.1.0]tridec-2-yloxypropyl)amine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, 3-(4-piperidinyloxy)pyridine and 3-((3S)-3-pyrrolidinyloxy)pyridine.

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines and arylthioalkylamines, including pyridyloxylalkylamines, phenoxyalkylamines, pyridylthiolalkylamines and phenylthioalkylamines. Exemplary compounds include (2-(5-bromo(3-pyridylthio))ethyl)methylamine, (2-(5-bromo(3-pyridylthio))isopropyl)methylamine, (2-(5-bromo(3-pyridylthio))propyl)methylamine, (3-(5-bromo(3-pyridylthio))propyl)methylamine, 3-((3S)-3-pyrrolidinyloxy)pyridine, 3-(4-piperidinyloxy)pyridine, 3-(1-methyl-4-piperidinyloxy)pyridine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, and methyl(3-tricyclo[7.3.1.0]tridec-2-yloxypropyl)amine.